业界动态监管公开信息 · FDA待译

Antimicrobial Resistance

FDA Drugs · 2026-11-14 23:59

正文 · 中文译文

抗微生物药物耐药性 FDA在抗微生物药物耐药性(AMR)防范与应对中的作用,以及关于AMR的信息 医疗对策问题 先进制造 抗微生物药物耐药性 埃博拉 猴痘 儿科医疗对策 面向消费者的防范信息 放射性及核应急防范 天花防范与应对 寨卡病毒 图片 说明 耐甲氧西林金黄色葡萄球菌(MRSA,棕色)被细胞碎片包围的扫描电子显微照片。MRSA对多种抗生素治疗具有耐药性。(来源:NIAID) 最新动态 | FDA的作用与战略方针 产品开发 | 抗微生物药物管理 监测与监控 | 监管科学 FDA出版物 | 面向消费者的信息 新闻稿与声明 | 活动 跨机构合作 | 联系FDA 抗微生物药物耐药性(AMR)——微生物(细菌、病毒、真菌、寄生虫)抵抗药物作用的能力——是一个严重、复杂且代价高昂的公共卫生问题。 根据美国疾病控制与预防中心的数据,美国每年至少发生280万例抗生素耐药感染,超过35,000人因此死亡。抗击AMR需要医疗保健和兽医领域的多方面努力。 最新动态 2026年2月12日:FDA已定稿GFI #273:为批准用于食用动物的医学重要抗菌药物界定使用期限。该指南就动物药品申办者如何自愿为一部分已批准用于食用动物、但目前缺乏明确使用期限的医学重要抗菌药物设定明确使用期限提出建议。 2025年1月8日:FDA发布了一份征求意见请求(RFC),就新机遇和新出现的监测需求征求公众意见,以供可能纳入即将出台的《国家抗菌药物耐药性监测系统(NARMS)2026-2030战略计划》。关于该RFC的《联邦公报》通知包括提交意见的说明,以及旨在促使提交有帮助意见的具体问题和信息请求。为期75天的意见征询期将于2025年1月10日至3月26日开放。 2024年11月18日:新的消费者文章和视频现已上线!了解如何安全使用抗生素,以便您康复、保护自己和家人,并对抗抗菌药物耐药性。 2024年10月10日:FDA宣布发布《2023年用于食用动物的抗菌药物销售或分销摘要报告》。2023年数据表明,美国批准用于食用动物的医学重要抗菌药物的销售和分销在2022年至2023年间下降了2%;这代表自2015年销售峰值以来下降了37%。 2024年10月9日:美国环境保护署(EPA)最终确定了其扩大联邦协作审查抗细菌和抗真菌农药的框架。在制定该框架过程中,EPA在美国白宫科学技术政策办公室的监督下,与美国人卫生与公众服务部(HHS)和美国农业部(USDA)进行了协调。该框架建立了一个流程,使EPA能够考虑其他联邦机构就抗细菌或抗真菌农药的使用是否可能降低某些人和动物用抗细菌及抗真菌药物有效性所提供的意见。 FDA的角色与战略方针 抗微生物药物耐药性被公认为日益严重的全球威胁。2014年,白宫宣布了《抗击耐药细菌国家战略》(CARB),强调需要采取协调一致的跨机构应对措施来应对这一威胁。FDA一直并继续在这些努力中发挥不可或缺的作用。 FDA的若干中心——包括药物评价与研究中心(CDER)、器械与放射健康中心(CDRH)、生物制品评价与研究中心(CBER)、兽药中心(CVM)、国家毒理学研究中心(NCTR)以及首席科学家办公室——在抗击AMR方面发挥关键作用。 美国食品药品监督管理局(FDA)致力于应对抗菌药物耐药性(AMR)带来的挑战,通过帮助保护现有抗菌药物的有效性,并促进可有助于减少AMR细菌出现和传播的新医疗产品的开发。 FDA与美国国内和国际合作伙伴合作,主动应对与AMR日益增长的威胁相关的复杂挑战,具体通过以下方式: 促进针对AMR的高效产品开发,包括开发新型抗菌药物、诊断检测和疫苗 促进抗菌药物的适当和负责任使用,并传播信息以推广有助于减缓耐药性发展的干预措施 支持开发和改进用于监测抗菌药物使用和耐药性的工具,使利益相关者能够更好地追踪、治疗或应对AMR暴发 推进监管科学,以开发工具、标准和方法,促进科学技术突破性发现转化为创新、安全且有效的医疗产品 为实现这一使命,FDA将继续与国会、美国其他政府机构的合作伙伴以及其他利益相关者协作,寻找更多预防、检测和应对AMR的方法。 产品开发 FDA与产品申办者和其他政府机构密切合作,促进针对AMR的高效产品开发,包括新型抗菌药物、生物制品(包括人用疫苗)和诊断产品。 采用产品开发计划与激励措施 FDA在适当情况下采用多种机制,帮助加快人用医疗产品的开发和可获得性:快速通道认定、优先审评和突破性疗法认定。 根据《立即产生抗生素激励措施》(GAIN,提交国会的报告;PDF,545 KB),FDA被授权提供五年的独占期延长,以激励新型合格传染病产品(QIDPs)(PDF,390 KB)的开发。QIDP被定义为“用于人类、旨在治疗严重或危及生命的感染(包括由耐药抗菌或抗真菌病原体引起的感染)的抗菌或抗真菌药物”。截至2018年8月,FDA已批准15个用于细菌或真菌感染的新QIDP。 由国会在《21世纪治愈法案》下设立的抗菌和抗真菌药物有限人群途径(LPAD途径),是帮助推进针对需求未得到满足的有限患者人群的抗微生物药物开发的新举措。 FDA还在与其他机构(包括医疗保险和医疗补助服务中心(CMS))讨论,以探索对某些满足关键患者和公共卫生需求的新型抗菌药物进行报销的方式。 鼓励新型和非传统产品以及新工具的的开发 FDA正在努力推进非传统抗微生物产品的开发,包括: 噬菌体(感染细菌、在其内复制并最终破坏细菌的病毒) 活体生物治疗产品(LBP)(满足以下条件的生物制品:1)含有活体微生物,如细菌;2)适用于预防、治疗或治愈人类疾病或病症;3)不是疫苗)另见CBER:活体生物治疗产品的早期临床试验:化学、生产和控制信息(行业指南)(PDF,174 KB) 微生物组疗法(例如,用于移植的粪便微生物群(FMT))另见CBER:粪便微生物群移植产品的监管考虑。Cell Host & Microbe 27:173-175, 2020; DOI 10.1016/j.chom.2020.01.018 免疫调节剂 FDA还在努力推进针对导致AMR的微生物的疫苗研发。 另见CBER:开发疫苗以预防全球传染病的通用原则(行业指南)(PDF,58 KB) 用于检测与微生物病原体相关的AMR的IVD器械 FDA鼓励开发新型体外诊断(IVD)器械,用于检测与微生物病原体相关的AMR。另见:抗菌药物敏感性试验——帮助医疗保健提供者确定适当的抗菌药物治疗。 在检索与AMR相关的器械批准信息时,了解与AMR相关器械类别对应的产品代码会有所帮助。 您可以在CDRH产品分类数据库中,通过在“device”部分搜索术语susceptibility、antimicrobial或resistance来找到这些代码。 虽然并非完整列表,但与抗菌药物耐药性(AMR)相关器械获批相关的产品代码示例包括:JTN、JWY、LON、LTT、LRG、LTW、PEN、PAM 和 POC。 这些产品代码包括表型抗菌药物敏感性试验(AST)器械以及通过其他方式(如遗传标记)确定AMR的器械。(FDA维护一份已获许可或批准的微生物核酸检测器械清单;请注意,该清单还包括其他不检测耐药遗传标记的器械。) 了解产品代码还可以在检索PMA、de novo和510(k)数据库时更容易找到特定的AMR相关器械获批信息。 2024年4月30日:BioMérieux因两个孔中头孢曲松抗生素浓度较高而召回VITEK 2 AST卡,该卡为一种AST试剂盒。该试剂盒用于检测细菌对抗生素的敏感性。 近期获批的体外诊断(IVD)器械,包括抗菌药物敏感性试验(AST)器械,包括:2024年2月15日:FDA批准Selux Diagnostics, Inc.的PBC[阳性血培养]分离器配合Selux抗菌药物敏感性试验(AST)系统在美国上市。PBC分离器配合Selux AST系统是一种自动化实验室接种制备系统,旨在与阳性血培养样本配合使用,可在无需传统过夜传代培养的情况下用于定量体外抗菌药物敏感性试验。 2023年7月6日:FDA 批准了 HardyDisk AST 舒巴坦/度洛巴坦 10/10μg(SUD20)(K231568),这是一种纸片扩散法药敏试验,用于舒巴坦/度洛巴坦的体外药敏检测,该新药获批用于治疗由鲍曼不动杆菌-醋酸钙不动杆菌复合群引起的医院获得性细菌性肺炎(HABP)和呼吸机相关性细菌性肺炎(VABP)。该检测方法在新药获批后仅6周即获得批准。 2023年7月5日:FDA 批准了 VITEK 2 AST-革兰阳性达托霉素(≤0.12 - ≥8 µg/mL)(K230864),这是经典肉汤稀释法的小型化、简化和自动化版本,用于测定达托霉素的最低抑菌浓度,该抗生素针对粪肠球菌检测的折点已更新。此外,由于 FDA 认可了折点,还增加了对耐万古霉素粪肠球菌检测的声称。 2023年5月4日:FDA 批准了 BD Kiestra 耐甲氧西林金黄色葡萄球菌(MRSA)应用程序(K213280),这是一种体外诊断软件程序,与 BD Kiestra 实验室自动化解决方案配合使用,用于对显色培养基上的微生物菌落进行定性评估,以辅助预防和控制耐甲氧西林金黄色葡萄球菌(MRSA)感染。 2023年4月19日:FDA通过510(k)上市前通知途径,批准Selux AST系统(K211748)与Selux革兰阴性综合检测板配合使用。此前,该系统已于今年早些时候获批(K211759)与Selux革兰阳性综合检测板配合使用。Selux AST系统是一种用于抗菌药物敏感性试验的体外诊断检测系统。该检测用于确定微生物对某种抗菌药物是敏感还是耐药,以帮助医生选择合适的药物来治疗感染。与既往系统相比,Selux AST系统可同时检测更多数量的药物及药物浓度。这两个检测板还具备在未来扩展纳入新药物的能力。敏感性检测系统使用FDA认可的临界值(称为药敏试验解释标准或折点),以提示药物是否可能有效(低于临界值的药物浓度可能有效,高于临界值的药物浓度则可能无效)。由于折点可更新以维持药物的临床成功率,Selux AST系统还附带前瞻性变更方案获批,允许开发商无需向FDA额外提交上市前申请即可更新折点。这是FDA持续致力于推进安全有效的抗菌药物敏感性检测可及性的最新范例,旨在帮助医疗专业人员做出更明智的决策,用于pa 患者。 2023年3月21日:FDA批准了Sensititre 20–24小时流感嗜血杆菌/肺炎链球菌MIC或折点药敏系统,联合德拉沙星,稀释范围为0.00025-8 µg/ml(肺炎链球菌)和0.000125-8 µg/ml(流感嗜血杆菌)(K223844),这是经典肉汤稀释法的小型化版本,用于测定德拉沙星的最低抑菌浓度,德拉沙星是一种获批用于治疗社区获得性细菌性肺炎(CABP)和急性细菌性皮肤及皮肤结构感染(ABSSSI)的抗生素。新增了对从CABP中分离的肺炎链球菌和流感嗜血杆菌分离株进行检测的声称。 2023年3月20日:FDA批准了Colibri系统(K223245),这是一种自动化分析前处理器,可挑取孤立菌落以制备用于细菌鉴定的MALDI-TOF MS靶板,以及用于抗菌药物敏感性试验的已知浓度微生物悬液。该系统是先前已批准半自动化系统的工作流程更新版本。 2023年3月10日:FDA批准了Sensititre YeastOne药敏系统,联合氟康唑,稀释范围为0.12-128 μg/mL(K221198),这是经典肉汤稀释法的小型化版本,用于测定氟康唑的最低抑菌浓度,氟康唑是一种抗真菌药,具有更新后的折点,用于检测白念珠菌、光滑念珠菌和近平滑念珠菌。 2023年3月9日:FDA批准了VITEK 2 AST-革兰阴性磷霉素(≤4 - ≥256 µg/mL)(K222430),这是经典肉汤稀释法的小型化、简化及自动化版本,用于测定磷霉素的最低抑菌浓度,磷霉素是一种用于治疗尿路感染的抗生素。 2023年2月16日:FDA批准了VITEK 2 AST-革兰阴性普拉佐米星(≤0.5 – ≥16 μg/mL)(K223478),这是经典肉汤稀释法的小型化、简化及自动化版本,用于测定普拉佐米星的最低抑菌浓度,普拉佐米星是一种用于治疗复杂性尿路感染的抗生素。 2023年2月9日:FDA批准了VITEK 2 AST-革兰阴性头孢唑林(≤1 – ≥32 μg/mL)(K222073),这是经典肉汤稀释法的小型化、简化及自动化版本,用于测定头孢唑林的最低抑菌浓度,头孢唑林是一种用于治疗各种感染以及用于围手术期预防以减少某些术后感染发生率的抗生素。 2023年2月3日:FDA批准了VITEK 2 链球菌四环素(≤ 0.25 - ≥ 16 μg/ml)(K223481),这是经典肉汤稀释法的小型化、简化及自动化版本,用于测定四环素的最低抑菌浓度,四环素是一种具有更新折点的抗生素,用于检测肺炎链球菌、化脓性链球菌(A组β溶血性链球菌)和链球菌属β溶血群菌种。 2023年1月27日:FDA批准了VITEK 2 AST-革兰阳性菌莫西沙星(≤0.25 - ≥ 8μg/ml)(K220803),这是经典肉汤稀释法的小型化、简化及自动化版本,用于测定莫西沙星的最低抑菌浓度,该抗生素针对粪肠球菌、金黄色葡萄球菌及其他葡萄球菌属的检测折点已更新。 2023年1月20日:FDA批准了Sensititre YeastOne药敏系统联合卡泊芬净,稀释范围为0.015-16ug/ml(K221899),这是经典肉汤稀释法的小型化版本,用于测定卡泊芬净的最低抑菌浓度,该抗真菌药物针对念珠菌属的检测折点已更新。 2023年1月18日:FDA批准了Selux AST系统;型号AST Gen 1.0(K211759),这是经典肉汤稀释法的半自动化和小型化版本,使用Selux革兰阳性菌检测板同时测定15种抗菌药物对特定肠球菌和葡萄球菌属的最低抑菌浓度,代表35种不同的抗菌药物/微生物组合。与传统96孔板不同,384孔板便于在新型抗菌药物可用时添加进行检测。 2022年12月21日:FDA批准了BD BBL Sensi-Disc头孢地尔30ug(FDC-30)(K221826),这是一种纸片扩散法检测,用于头孢地尔的体外药敏试验,该抗生素近期获批用于治疗复杂性尿路感染。 2022年10月13日:FDA批准了VITEK 2 AST-革兰阳性菌头孢西丁检测(K220805),这是一种小型化、简化且自动化的倍比稀释技术版本,旨在

正文 · 英文原文

Antimicrobial Resistance FDA's role in antimicrobial resistance (AMR) preparedness and response, and information about AMR MCM Issues Advanced Manufacturing Antimicrobial Resistance Ebola Mpox Pediatric Medical Countermeasures Preparedness Information for Consumers Radiological and Nuclear Emergency Preparedness Smallpox Preparedness and Response Zika Virus Image Caption Scanning electron micrograph of methicillin-resistant Staphylococcus aureus (MRSA, brown) surrounded by cellular debris. MRSA resists treatment with many antibiotics. (Credit: NIAID) What's new | The FDA's role and strategic approach Product development | Antimicrobial stewardship Surveillance and monitoring | Regulatory science FDA publications | Information for consumers Press and statements | Events Interagency collaboration | Contact the FDA Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. According to the Centers for Disease Control and Prevention, each year in the United States at least 2.8 million antibiotic-resistant infections occur, and more than 35,000 people die as a result. Combating AMR requires multifaceted efforts in both the healthcare and veterinary sectors. What's new February 12, 2026: The FDA has finalized GFI #273: Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals. This guidance provides recommendations on how animal drug sponsors may voluntarily establish defined durations of use for a subset of approved medically important antimicrobial drugs that are approved for use in food-producing animals and currently lack a defined duration of use. January 8, 2025: The FDA released a request for comments (RFC) soliciting public input on new opportunities and emergent monitoring needs for possible inclusion in the forthcoming National Antimicrobial Resistance Monitoring System (NARMS) 2026-2030 Strategic Plan. The Federal Register notice about the RFC includes instructions for submitting comments, as well as specific questions and requests for information meant to prompt helpful submissions. The 75-day comment period will be open from January 10 to March 26, 2025. November 18, 2024: New consumer article and video now available! Learn how you can safely use antibiotics so you can get well, protect yourself and your family, and combat antimicrobial resistance. October 10, 2024: The FDA announced the publication of the 2023 Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. The 2023 data indicate that U.S. sales and distribution of medically important antimicrobial drugs approved for use in food-producing animals decreased by 2% between 2022 and 2023; this represents a 37% decrease in sales since the sales peaked in 2015. October 9, 2024: The U.S. Environmental Protection Agency (EPA) finalized its framework for expanding federal collaboration on the review of antibacterial and antifungal pesticides. In developing the framework, EPA coordinated with the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Agriculture (USDA), under the oversight of the White House Office of Science and Technology Policy. The framework establishes a process for EPA to consider input from the other federal agencies on whether use of antibacterial or antifungal pesticides might reduce the effectiveness of some human and animal antibacterial and antifungal drugs. The FDA's role and strategic approach Antimicrobial resistance is recognized as a growing global threat. In 2014, the White House announced the National Strategy for Combating Antibiotic-Resistant Bacteria (CARB), underscoring the need for a coordinated inter-agency response to this threat. The FDA has been and continues to be integral in these efforts. Several of FDA’s Centers—including the Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), Center for Biologics Evaluation and Research (CBER), Center for Veterinary Medicine (CVM), National Center for Toxicological Research (NCTR), and the Office of the Chief Scientist—play key roles in combating AMR. The FDA is dedicated to addressing the challenges AMR presents by helping to preserve the effectiveness of currently available antimicrobial drugs and promoting the development of new medical products that can help reduce the emergence and spread of AMR bacteria. Working with both domestic and international partners, the FDA is proactively addressing the complex challenges associated with the growing threat of AMR by: Facilitating efficient product development to address AMR, including the development of new antimicrobials, diagnostic tests, and vaccines Promoting the appropriate and responsible use of antimicrobials and disseminating information promoting interventions that help slow the development of resistance Supporting the development and enhancement of tools for conducting surveillance of antimicrobial use and resistance so stakeholders can better track, treat, or respond to AMR outbreaks Advancing regulatory science to develop the tools, standards, and approaches to facilitate the translation of breakthrough discoveries in science and technology into innovative, safe, and effective medical products To achieve this mission, the FDA will continue to work collaboratively with Congress, its partners at other U.S. government agencies, and other stakeholders to find additional ways to prevent, detect, and address AMR. Product development The FDA works closely with product sponsors and other government agencies to facilitate efficient product development to address AMR, including new antimicrobial drugs, biologics (including human vaccines), and diagnostics. Employing product development program and incentives The FDA employs a variety of mechanisms, where appropriate, to help speed the development and availability of medical products for humans: Fast track designation, priority review, and breakthrough therapy designation. Under Generating Antibiotic Incentives Now (Report to Congress; PDF, 545 KB), or GAIN, the FDA is authorized to provide a five-year extension of exclusivity to incentivize the development of new Qualified infectious disease products (QIDPs) (PDF, 390 KB). A QIDP is defined as “an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by an antibacterial or antifungal resistant pathogen.” As of August 2018, the FDA has approved 15 new QIDPs for bacterial or fungal infections. Established by Congress under the 21st Century Cures Act, the Limited Population Pathway for Antibacterial and Antifungal Drugs, or LPAD pathway, is a new step to help advance development of antimicrobial drugs for limited populations of patients with unmet need. The FDA is also in discussion with other agencies including the Centers for Medicare and Medicaid Services (CMS) to explore the means for reimbursement of certain new antibacterial drugs that meet critical patient and public health needs. Encouraging the development of novel and nontraditional products, and new tools The FDA is working to advance the development of nontraditional antimicrobial products including: Bacteriophages (viruses that infect, replicate within, and ultimately destroy bacteria) Live biotherapeutic products (LBP) (biological products that 1) contain live organisms, such as bacteria; 2) are applicable to the prevention, treatment, or cure of a disease or condition of human beings; and 3) are not a vaccine)Also see from CBER: Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information (Guidance for Industry) (PDF, 174 KB) Microbiome therapies (e.g., fecal microbiota for transplantation (FMT))Also see from CBER: Regulatory Considerations for Fecal Microbiota Transplantation Products. Cell Host &Microbe 27:173-175, 2020; DOI 10.1016/j.chom.2020.01.018 Immune-modulators The FDA is also working to advance the development of vaccines for organisms contributing to AMR. Also see from CBER: General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases (Guidance for Industry) (PDF, 58 KB) IVD devices for detection of AMR associated with microbial pathogens The FDA encourages the development of novel in vitro diagnostic (IVD) devices for detection of AMR associated with microbial pathogens. Also see: Antimicrobial Susceptibility Testing - Helping Health Care Providers Determine the Appropriate Antimicrobial Agent for Treatment When searching for AMR-related device approvals it is helpful to know the associated Product Code for the class of AMR-related devices. You can find these codes in the CDRH Product Classification database, by searching for the terms susceptibility, antimicrobial, or resistance in the “device” section. While not a complete list, examples of Product Codes associated with AMR-related device approvals include: JTN, JWY, LON, LTT, LRG, LTW, PEN, PAM, and POC. These Product Codes include phenotypic antimicrobial susceptibility test (AST) devices and devices that determine AMR by other means, such as genetic markers. (FDA maintains a list of cleared or approved Microbial Nucleic Acid Devices; please note that this list also includes other devices that do not detect genetic markers of resistance.) Knowing the Product Code also makes it easier to find specific AMR-related device approvals when searching the PMA, de novo, and 510(k) databases. April 30, 2024: BioMérieux is recalling VITEK 2 AST cards, an AST kit, due to a higher concentration of ceftriaxone antibiotic in two wells. This kit is used for testing how sensitive bacteria are to antibiotics. Recently cleared IVD devices, including Antimicrobial Susceptibility Test (AST) devices, include:February 15, 2024: The FDA cleared the PBC [positive blood culture] Separator with Selux Antimicrobial Susceptibility Testing (AST) System from Selux Diagnostics, Inc. to be marketed in the U.S. The PBC Separator with Selux AST System is an automated lab inoculation preparation system intended for use with positive blood culture samples that can be used for quantitative in vitro antimicrobial susceptibility testing without the traditional overnight subculture. July 6, 2023: The FDA cleared HardyDisk AST Sulbactam/Durlobactam 10/10μg (SUD20) (K231568), a disk diffusion assay for in vitro susceptibility testing of Sulbactam/Durlobactam, a new drug approved for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii-calcoaceticus complex. This assay was cleared just 6 weeks after new drug approval. July 5, 2023: The FDA cleared VITEK 2 AST-Gram Positive Daptomycin (≤0.12 - ≥8 µg/mL) (K230864), a miniaturized, abbreviated and automated version of the classic broth dilution method to determine the minimum inhibitory concentration of daptomycin, an antibiotic with updated breakpoints for testing Enterococcus faecalis. In addition, claims for testing vancomycin-resistant E. faecalis were added due to FDA recognition of breakpoints. May 4, 2023: The FDA cleared the BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) Application (K213280), an in vitro diagnostic software program for use with the BD Kiestra Laboratory Automation Solution for the qualitative assessment of microbial colonies on chromogenic culture media to aid in the prevention and control of methicillin-resistant Staphylococcus aureus (MRSA) infection. April 19, 2023: The FDA cleared the Selux AST System (K211748) for use with the Selux Gram-Negative Comprehensive Panel through the 510(k) premarket notification pathway. This follows clearance (K211759) of the system earlier this year for use with the Selux Gram-Positive Comprehensive Panel. The Selux AST System is an in vitro diagnostic test system used for antimicrobial susceptibility testing. This testing is performed to determine whether an organism is susceptible or resistant to an antimicrobial drug to help physicians select the appropriate drug to treat an infection. The Selux AST System allows for simultaneous testing of a larger number of drugs and drug concentrations than previous systems. The two panels also have the ability to expand to incorporate new drugs in the future. Susceptibility testing systems use FDA-recognized cut-off values (referred to as susceptibility test interpretive criteria or breakpoints), to indicate whether the drug is likely to be effective (drug concentrations below the cut-off are likely to be effective, and drug concentrations above the cut-off are not likely to be effective). Since breakpoints can be updated to maintain clinical success of the drug, the Selux AST System was also cleared with a prospective change protocol, allowing the developer to update breakpoints without an additional premarket submission to the FDA. This is the latest example of the FDA’s ongoing commitment to advance access to safe and effective antimicrobial susceptibility testing intended to aid healthcare professionals in making more informed decisions for patients. March 21, 2023: The FDA cleared the Sensititre 20–24-hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Delafloxacin in the dilution range of 0.00025-8 µg/ml (Streptococcus pneumoniae) and 0.000125-8 µg/ml (Haemophilus influenzae) (K223844) a miniaturized version of the classic broth dilution method to determine the minimum inhibitory concentration of delafloxacin, an antibiotic approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Claims were added for testing Streptococcus pneumoniae and Haemophilus influenzae isolates recovered from CABP. March 20, 2023: The FDA cleared the Colibri System (K223245), an automated pre-analytical processor that picks isolated colonies to prepare MALDI-TOF MS target slides for bacterial identification and microbial suspensions at a known concentration for antimicrobial susceptibility testing. This system is an updated workflow from the previously cleared semi-automated system. March 10, 2023: The FDA cleared the Sensititre YeastOne Susceptibility System with Fluconazole in the dilution range of 0.12-128 μg/mL (K221198), a miniaturized version of the classic broth dilution method to determine the minimum inhibitory concentration of fluconazole, an antifungal agent with updated breakpoints for testing C. albicans, C. glabrata, and C. parapsilosis. March 9, 2023: The FDA cleared the VITEK 2 AST-Gram Negative Fosfomycin (≤4 - ≥256 µg/mL) (K222430), a miniaturized, abbreviated and automated version of the classic broth dilution method to determine the minimum inhibitory concentration of Fosfomycin, an antibiotic used for the treatment of urinary tract infection. February 16, 2023: The FDA cleared the VITEK 2 AST-Gram Negative Plazomicin (≤0.5 – ≥16 μg/mL) (K223478), a miniaturized, abbreviated and automated version of the classic broth dilution method to determine the minimum inhibitory concentration of Plazomicin, an antibiotic used for the treatment of complicated urinary tract infection. February 9, 2023: The FDA cleared the VITEK 2 AST-Gram Negative Cefazolin (≤1 – ≥32 μg/mL) (K222073), a miniaturized, abbreviated and automated version of the classic broth dilution method to determine the minimum inhibitory concentration of Cefazolin, an antibiotic used for the treatment of various infections as well as for perioperative prophylaxis to reduce incidence of certain postoperative infections. February 3, 2023: The FDA cleared the VITEK 2 Streptococcus Tetracycline (≤ 0.25 - ≥ 16 μg/ml) (K223481), a miniaturized, abbreviated and automated version of the classic broth dilution method to determine the minimum inhibitory concentration of Tetracycline an antibiotic with updated breakpoints for testing Streptococcus pneumoniae, Streptococcus pyogenes (Group A Beta-Hemolytic streptococci) and Streptococcus spp. β-Hemolytic Group species. January 27, 2023: The FDA cleared the VITEK 2 AST-Gram Positive Moxifloxacin (≤0.25 - ≥ 8μg/ml) (K220803), a miniaturized, abbreviated and automated version of the classic broth dilution method to determine the minimum inhibitory concentration of Moxifloxacin an antibiotic with updated breakpoints for testing Enterococcus faecalis, Staphylococcus aureus and other Staphylococcus species. January 20, 2023: The FDA cleared the Sensititre YeastOne Susceptibility System with Caspofungin in the dilution range of 0.015-16ug/ml (K221899), a miniaturized version of the classic broth dilution method to determine the minimum inhibitory concentration of Caspofungin, an antifungal agent with updated breakpoints for testing Candida spp. January 18, 2023: The FDA cleared the Selux AST System; Model AST Gen 1.0 (K211759), a semi-automated and miniaturized version of the classic broth dilution method to simultaneously determine the minimum inhibitory concentration of 15 antimicrobials against select Enterococcus and Staphylococcus species, representing 35 different antimicrobial/organism combinations using the Selux Gram Positive Panel. Unlike traditional 96-well panels, the 384-well panel facilitates addition of new antimicrobials for testing as they become available. December 21, 2022: The FDA cleared the BD BBL Sensi-Disc Cefiderocol 30ug (FDC-30) (K221826), a disk diffusion assay for in vitro susceptibility testing of Cefiderocol, an antibiotic recently approved for the treatment of complicated urinary tract infections. October 13, 2022: The FDA cleared the VITEK 2 AST-Gram Positive Cefoxitin (K220805), a miniaturized, abbreviated and automated version of the doubling dilution technique designed

摘要 待译

Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

English
Antimicrobial Resistance
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界